Promore Pharma

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company aims to develop first-in-class pharmaceuticals for indications with unmet medical needs, as there are currently few effective prescription drugs available. Two of the company’s projects are in clinical development and have strong safety profiles, as these products are based on endogenous substances. The outcomes of these projects will be used to prevent scar formation after surgery. The company’s product PXL01 (Enkeltserin) is being prepared for Phase II clinical trials, while Ropocamptides (LL-37) was recently evaluated in a Phase IIb clinical study, showing positive results in patients with venous leg ulcers (VLUs). This product also has potential applications in other indications, such as preventing adverse tissue adhesion (adhesions) following various surgical procedures and treating diabetic foot ulcers. The company’s products are protected by multiple international patent families, with protection extending until 2030 and beyond.The company is small yet cost-efficient, without its own laboratories or research facilities. It operates through a network of high-quality contract research organizations (CROs) and contract manufacturing organizations (CMOs). The company has experienced consultants in all key aspects of strategic planning, including product development, regulatory affairs, and the design and execution of clinical trials.